Employer-Sponsored Health Plans: New Risks

Health and welfare plan cost have come roaring back in a "post covid" world. Contractors face new cost increases and risks in their medical plans - with health care inflation showing no signs of abatement for 2024/2025. In order to mitigate the cost pressures, employers will need to assertively and proactively manage emerging risks to the plan. One such risk are GLP-1 diabetes medications and anti-obesity medications (AOM's).

This session will arm attendees with:

• The ability to use data and demographics to identify emerging risks/costs in the medical plan.
• The tools to decode "post-covid" medical plan costs and trends - and the "new normal" for contractors.
• The specific "AOM's and GLP-1" Rx (obesity and diabetes drubs) of the risks and costs to contractors; and tools to manage the risk appropriately (tangible instruction - actionable steps for cost controls).
• The ability to distinguish between Noise vs. Signal for coming plan year. Provide the tools to distinguish between plan offerings/"point solutions" (i.e. captives, Rx carve outs etc) that make a different vs. those that are simply "noise".
• Understand the leading indicators for medical inflation and the interplay with labor costs - and what this means for contractors hiring/retention and benefit offering cost profile.

The estimated time to complete the course and final exam is approximately 75 minutes, depending on the pace of the learner.